<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05082675</url>
  </required_header>
  <id_info>
    <org_study_id>NMAM2000</org_study_id>
    <nct_id>NCT05082675</nct_id>
  </id_info>
  <brief_title>Stem Cell Translpantation in Multiple Myeloma</brief_title>
  <official_title>A Phase-II Study Comparing Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Following Autologous Transplantation to Autologous Transplantation Alone in Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Society for Blood and Marrow Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Society for Blood and Marrow Transplantation</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether autologous transplantation (using the&#xD;
      patient's own stem cells from the blood), followed by non-myeloablative (i.e. less intense)&#xD;
      allogeneic transplantation (where the blood stem cells from a sibling donor are used for the&#xD;
      transplantation) improves the outcome in patients with newly diagnosed multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial includes a natural (no available HLA-identical sibling donor) control arm.&#xD;
      Patients with newly diagnosed multiple myeloma without a sibling are initially treated with&#xD;
      conventional chemotherapy followed by conventional single or double autologous transplant&#xD;
      (PBSCT). Data from this group is used as part of the control group.&#xD;
&#xD;
      Eligible patients with one or more sibling are offered to participate in the main trial arm.&#xD;
      Those who decline are asked to consider taking part in the control group (autograft only).&#xD;
&#xD;
      Patients consenting to participate in the main study first receive the PBSCT, followed by the&#xD;
      HLA-matched non-myeloablative allograft (matched for HLA -A, -B, -C, -DRB1).&#xD;
&#xD;
      All study patients receive four to six cycles of VAD (or alternative regimens specified in&#xD;
      protocol) before PBSCT as first line treatment. Study entry starts at the time of starting&#xD;
      conditioning for autologous transplantation. The search for an identical sibling donor begins&#xD;
      as soon as the patient has consented to participate in the study.&#xD;
&#xD;
      The allograft is performed when the patient has restored their marrow function but no earlier&#xD;
      than 3 months following PBSCT.&#xD;
&#xD;
      The aim is to demonstrate a difference in outcome (progression free survival, transplant&#xD;
      related mortality, relapse rate, and survival).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Progression free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transplant related mortality</measure>
    <time_frame>5 years</time_frame>
    <description>Transplant related mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete hematological and molecular remission rate</measure>
    <time_frame>5 years</time_frame>
    <description>Complete hematological and molecular remission rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>5 years</time_frame>
    <description>Relapse rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Survival</description>
  </secondary_outcome>
  <enrollment>260</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HLA Matched allogeneic transplant</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed Stage-II and III multiple myeloma (According to Durie and Salmon&#xD;
             classification)&#xD;
&#xD;
          -  Age under 70 years&#xD;
&#xD;
          -  Life expectancy over 3 months&#xD;
&#xD;
          -  Patients must be able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious concomitant medical disease which would limit life span or the ability to&#xD;
             tolerate chemotherapy&#xD;
&#xD;
          -  Severe cardiac failure (ejection fraction &lt;40%)&#xD;
&#xD;
          -  Impairment of renal function at diagnosis is not per se reason for exclusion but&#xD;
             patients with severe impaired renal function (GFR &lt;50 ml/min) after initial VAD (or&#xD;
             VAD like) induction treatment are excluded&#xD;
&#xD;
          -  Severe impairment of liver function (bilirubin &gt;2 times upper limit of normal)&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Other major organ system dysfunction (GI, neurological, psychiatric dysfunction) that&#xD;
             impairs tolerance of therapy or prolong hematological recovery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Björkstrand, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Huddinge University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University</name>
      <address>
        <city>Turku</city>
        <zip>52 20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ferrarotto</name>
      <address>
        <city>Catania</city>
        <zip>95100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Milano</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uni. Modena, Policlinico</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS, Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tromso</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huddinge University Hospital</name>
      <address>
        <city>Huddinge</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Faculty of Medicine</name>
      <address>
        <city>Ankara</city>
        <zip>06260</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.ebmt.org</url>
    <description>Sponsor's website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myeloma</keyword>
  <keyword>HLA-matched</keyword>
  <keyword>autologous</keyword>
  <keyword>allogeneic</keyword>
  <keyword>transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

